Skip to main content

Table 5 Normalized miRNA expression (2^(−Avg.(Delta(Ct)) in Group 2 (CML patients non-responsive to imatinib therapy) and Control Group (blood donors) of significant miRNAs calculated by Gene Globe Data Analysis Centre (QIAGEN)

From: Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

  Average Ct Average Delta(Ct) (Ct(miROI) - Average Ct(normalisation factor)) 2^(−Average(Delta(Ct))
Mature
ID
Control Group Standard Deviation Group 2 Standard Deviation Control Group Standard Deviation Group 2 Standard
Deviation
Control
Group
Group 2
hsa-miR-181a-5p 24.99 0.804605 26.01 1.340582 5.146885 0.734814 6.366369 0.836165 0.028225 0.012121
hsa-miR-182-5p 23.46 0.811293 22.21 1.120019 3.621528 0.636088 2.563155 0.647466 0.081248 0.169205
hsa-miR-26a-5p 21.11 0.829467 19.65 1.452098 1.264028 0.409326 0.005655 0.833271 0.416380 0.996088